| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The FASEB Journal, Vol 6, 3169-3176, Copyright © 1992 by The Federation of American Societies for Experimental Biology
REVIEWS |
M Oren
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
Alterations in the gene encoding the cellular p53 protein are perhaps the most frequent type of genetic lesions in human cancer. At the heart of these alterations is the abrogation of the tumor suppressor activity of the normal p53. In many cases this is achieved through point mutations in p53, which often result in pronounced conformational changes. Such mutant polypeptides, which tend to accumulate to high levels in cancer cells, are believed to exert a dominant negative effect over coexpressed normal p53. Extensive research on p53, especially in the course of the last 3 years, has already provided much insight into the biological and biochemical mechanisms that underlie its capacity to act as a potent tumor suppressor. There are now many indications that p53 may play a central role in the control of cell proliferation, cell survival, and differentiation. Nevertheless, despite the purported importance of p53 for such crucial processes, mice can develop apparently without any defect in the total absence of p53. This raises the possibility that p53 may become critically limiting only when normal growth control is lost.
This article has been cited by other articles:
|
|
 |
|
  M. K. Lee and K. Sabapathy The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo J. Cell Sci., June 1, 2008; 121(11): 1899 - 1906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tsvetkov, G. Asher, V. Reiss, Y. Shaul, L. Sachs, and J. Lotem Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin PNAS, April 12, 2005; 102(15): 5535 - 5540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Maruo, N. Ohara, J. Wang, and H. Matsuo Sex steroidal regulation of uterine leiomyoma growth and apoptosis Hum. Reprod. Update, May 1, 2004; 10(3): 207 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lotem, H. Gal, R. Kama, N. Amariglio, G. Rechavi, E. Domany, L. Sachs, and D. Givol Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes PNAS, May 27, 2003; 100(11): 6718 - 6723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Asher, J. Lotem, L. Sachs, C. Kahana, and Y. Shaul Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1 PNAS, October 1, 2002; 99(20): 13125 - 13130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Gao, H. Matsuo, S. Nakago, O. Kurachi, and T. Maruo p53 Tumor Suppressor Protein Content in Human Uterine Leiomyomas and Its Down-Regulation by 17{beta}-Estradiol J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3915 - 3920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. A.-E. Hussein and G. S. Wood Molecular Aspects of Melanocytic Dysplastic Nevi J. Mol. Diagn., May 1, 2002; 4(2): 71 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-M. Yuan, W. Li, H. Dalen, J. Lotem, R. Kama, L. Sachs, and U. T. Brunk Lysosomal destabilization in p53-induced apoptosis PNAS, April 30, 2002; 99(9): 6286 - 6291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Asher, J. Lotem, B. Cohen, L. Sachs, and Y. Shaul Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1 PNAS, January 23, 2001; (2001) 21558898. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. V. BLAGOSKLONNY p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect FASEB J, October 1, 2000; 14(13): 1901 - 1907. [Abstract] [Full Text]
|
|
|
|
|
|
J. Lotem and L. Sachs Different mechanisms for suppression of apoptosis by cytokines and calcium mobilizing compounds PNAS, April 14, 1998; 95(8): 4601 - 4606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Moallem and B. Hales The role of p53 and cell death by apoptosis and necrosis in 4-hydroperoxycyclophosphamide-induced limb malformations Development, January 8, 1998; 125(16): 3225 - 3234. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Naka, Y. Iwamoto, N. Shinohara, H. Chuman, and M. Tsuneyoshi p53 Accumulation in Malignant Bone Tumors: An Immunohistochemical Analysis of 217 Cases International Journal of Surgical Pathology, July 1, 1997; 5(1-2): 1 - 9. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. A. Hannun Apoptosis and the Dilemma of Cancer Chemotherapy Blood, March 15, 1997; 89(6): 1845 - 1853. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Qi, J. K. T. Wang, M. McMillian, and D. M. Chikaraishi Characterization of a CNS Cell Line, CAD, in which Morphological Differentiation Is Initiated by Serum Deprivation J. Neurosci., February 15, 1997; 17(4): 1217 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Maiyar, A. J. Huang, P. T. Phu, H. H. Cha, and G. L. Firestone p53 Stimulates Promoter Activity of the sgk Serum/Glucocorticoid-inducible Serine/Threonine Protein Kinase Gene in Rodent Mammary Epithelial Cells J. Biol. Chem., May 24, 1996; 271(21): 12414 - 12422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hurd, N. Khattree, P. Alban, K. Nag, S. C. Jhanwar, S. Dinda, and V. K. Moudgil Hormonal Regulation of the p53 Tumor Suppressor Protein in T47D Human Breast Carcinoma Cell Line J. Biol. Chem., December 1, 1995; 270(48): 28507 - 28510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Haupt, S Rowan, E Shaulian, K H Vousden, and M Oren Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes & Dev., September 1, 1995; 9(17): 2170 - 2183. [Abstract] [PDF]
|
|
|
|
|
|
K A Howes, N Ransom, D S Papermaster, J G Lasudry, D M Albert, and J J Windle Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes & Dev., June 1, 1994; 8(11): 1300 - 1310. [Abstract] [PDF]
|
|
|
|
 |
|
 R. L. Kerschmann, T. H. McCalmont, and P. E. LeBoit p53 Oncoprotein Expression and Proliferation Index in Keratoacanthoma and Squamous Cell Carcinoma Arch Dermatol, February 1, 1994; 130(2): 181 - 186. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Barak, A. Lupo, A. Zauberman, T. Juven, R. Aloni-Grinstein, E. Gottlieb, V. Rotter, and M. Oren Targets for Transcriptional Activation by Wild-type p53: Endogenous Retroviral LTR, Immunoglobulin-like Promoter, and an Internal Promoter of the mdm2 Gene Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 225 - 235. [Abstract] [PDF]
|
|
|
|
|
|
A.F. Gazdar, S. Bader, J. Hung, Y. Kishimoto, Y. Sekido, K. Sugio, A. Virmani, J. Fleming, D.P. Carbone, and J.D. Minna Molecular Genetic Changes Found in Human Lung Cancer and Its Precursor Lesions Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 565 - 572. [Abstract] [PDF]
|
|
|
|
 |
|
 C. C. Harris and M. Hollstein Clinical Implications of the p53 Tumor-Suppressor Gene N. Engl. J. Med., October 28, 1993; 329(18): 1318 - 1327. [Full Text]
|
|
|
|
|
|
G. Asher, J. Lotem, B. Cohen, L. Sachs, and Y. Shaul Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1 PNAS, January 30, 2001; 98(3): 1188 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-M. Yuan, W. Li, H. Dalen, J. Lotem, R. Kama, L. Sachs, and U. T. Brunk Lysosomal destabilization in p53-induced apoptosis PNAS, April 30, 2002; 99(9): 6286 - 6291. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
